<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(2)</volume><submitter>Shao Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The effect of perioperative chemotherapy on patients with lymph node-negative esophageal cancer (EC) is controversial. This study explored which EC patients, staged under the T1-3N0M0, would benefit from perioperative chemotherapy.&lt;h4>Methods&lt;/h4>Data on patients with diagnosed primary EC were retrieved from Surveillance, Epidemiology and End Results (SEER) database. Propensity score-matched (PSM) method was performed to balance baseline covariates. Multivariate Cox regression analysis and Kaplan-Meier curve were used to assess potential survival difference between patients undergoing surgery plus perioperative chemotherapy (SA + CT) and those undergoing surgery alone (SA).&lt;h4>Results&lt;/h4>In a total of 2,711 EC patients (T1-3N0M0), 166 patients underwent SA + CT and 2,54</pubmed_abstract><journal>Journal of thoracic disease</journal><pagination>995-1004</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7947537</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Survival benefit of perioperative chemotherapy for T1-3N0M0 stage esophageal cancer: a SEER database analysis.</pubmed_title><pmcid>PMC7947537</pmcid><pubmed_authors>Ye L</pubmed_authors><pubmed_authors>Wang XM</pubmed_authors><pubmed_authors>Shao Y</pubmed_authors><pubmed_authors>Wu QC</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Chen D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Survival benefit of perioperative chemotherapy for T1-3N0M0 stage esophageal cancer: a SEER database analysis.</name><description>&lt;h4>Background&lt;/h4>The effect of perioperative chemotherapy on patients with lymph node-negative esophageal cancer (EC) is controversial. This study explored which EC patients, staged under the T1-3N0M0, would benefit from perioperative chemotherapy.&lt;h4>Methods&lt;/h4>Data on patients with diagnosed primary EC were retrieved from Surveillance, Epidemiology and End Results (SEER) database. Propensity score-matched (PSM) method was performed to balance baseline covariates. Multivariate Cox regression analysis and Kaplan-Meier curve were used to assess potential survival difference between patients undergoing surgery plus perioperative chemotherapy (SA + CT) and those undergoing surgery alone (SA).&lt;h4>Results&lt;/h4>In a total of 2,711 EC patients (T1-3N0M0), 166 patients underwent SA + CT and 2,54</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Feb</publication><modification>2025-04-18T17:47:10.506Z</modification><creation>2025-02-19T01:40:28.87Z</creation></dates><accession>S-EPMC7947537</accession><cross_references><pubmed>33717572</pubmed><doi>10.21037/jtd-20-2877</doi></cross_references></HashMap>